3 ms·
There was an issue I read about with a drug where they did not test all the different dosages of a generic, and I think the behavior of one of the doses was not
by perl4ever 7y ago
There was an issue I read about with a drug where they did not test all the different dosages of a generic, and I think the behavior of one of the doses was not as expected because it didn't dissolve well or something.
This was a psychiatric drug, and so of course, reports of problems went unheeded for years because patients were assumed to be imagining things.
Saying "the drug does have to behave the same as the branded product" is like saying "the product as delivered does have to match the spec".
- refurb 7y agoYup. There have been a handful of approved generics that didn’t have bioequivalence to the branded. It’s not a perfect process, but it works in nearly all the cases.
- perl4ever 7y agoWe don't know that "it works in nearly all the cases". We know that in nearly all the cases, any issues don't rise to the level where the FDA or the public identifies them. I doubt that the system is constructed in such a way that nearly all the problems are identified. It seems to me that because drugs are developed to meet the absolute minimum standards for proving efficacy and safety, there's inherently going to be little if any margin for error in the manufacturing process and hardly any way to analyze problems. When reporting potential side effects, most drugs are going to be just above the noise level in their principle effect, so how are you going to determine what is a random unrelated issue and what is a negative side effect, and what is the consequence of a QA or design failure?